Systemic enzyme therapy in chronic venous disease: a review

Girish D. Bakhshi, Zarin S. Rangwala, Akansha R. Chauhan


Chronic venous disease (CVD), a sequel of venous insufficiency, has great medical and socioeconomic impact. Varicose veins and venous ulcer are amongst its commonest manifestations. In CVD, incompetent valves, weakened vascular walls, venous hypertension and increased permeability of venous walls lead to the release of proinflammatory mediators like tumor necrosis factor (TNF)-α, interleukin (IL)-1β, reactive oxygen species (R.O.S.), and reactive nitrogen species (R.N.S.) in the venous milieu. Pharmacotherapy with nonsteroidal anti-inflammatory drugs (NSAIDs) is often used to relieve pain caused by venous disease. However, there is a need for therapies that target the microcirculatory disorders and act on chronic inflammatory processes. Systemic enzyme therapy (SET), with orally administered combination of proteolytic enzymes- trypsin, bromelain, and flavonoid rutoside, has been used since decades for their anti-inflammatory, analgesic, anti-edematous, antithrombotic and antioxidant properties. This review discusses the various relevant pharmacodynamic properties demonstrated by the ingredients, followed by clinical studies of SET, which have demonstrated benefit in both subjective and objective parameters. These studies indicate that SET has good efficacy, tolerability and holds great promise to improve the quality of life of a patient with CVD.  



Chronic venous disease, Systemic enzyme therapy, Venous ulcer, Varicose veins

Full Text:



Ligi D, Croce L, Mannello F. Chronic venous disorders: the dangerous, the good, and the diverse. Int J Mol Sci. 2018;19(9):2544.

Devi A, Aathi M. Conservative Management of Varicose Veins. Int J Adv Nur Management. 2014;2(1):40-5.

Eberhardt R, Raffetto J. Chronic venous insufficiency. Circulation. 2014;130(4):333-46.

Antani M, Dattilo J. Varicose Veins. StatPearls 2019. Accessed on 20th May, 2021.

Santler B, Goerge T. Chronic venous insufficiency–a review of pathophysiology, diagnosis, and treatment. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2017;15(5):538-56.

Vasilev I, Bogdanec L, Shcherbin S. The efficacy of systemic enzyme therapy in the etiology. Bulletin of Russian State Medical University. 2016(5).

Spiridon M, Corduneanu D. Chronic venous insufficiency: a frequently underdiagnosed and undertreated pathology. Mædica. 2017;12(1):59-61.

Jünger M, Steins A, Hahn M, Häfner H. Microcirculatory dysfunction in chronic venous insufficiency (CVI). Microcirculation. 2000;7(1):S3-12.

Sinclair R, Ryan T. Proteolytic enzymes in wound healing: the role of enzymatic debridement. Australasian journal of dermatology. 1994;35(1):35-41.

Agale S. Chronic leg ulcers: epidemiology, aetiopathogenesis, and management. Ulcers. 2013;2013.

Wollina U, Abdel-Naser M, Mani R. A review of the microcirculation in skin in patients with chronic venous insufficiency: the problem and the evidence available for therapeutic options. Int J Low Extrem Wounds. 2006;5(3):169-80.

Messmore H, Bishop M, Wehrmacher W. Acute venous thrombosis: therapeutic choices for superficial and deep veins. Postgrad Med. 1991;89(7):73-7.

Jull A, Arroll B, Parag V, Waters J. Pentoxifylline for treating venous leg ulcers. Cochrane database of systematic reviews. 2007(3).

Smith P. Micronized purified flavonoid fraction and the treatment of chronic venous insufficiency: microcirculatory mechanisms. Microcirculation. 2000;7(S1):S35-40.

Nair B. Venous leg ulcer: Systemic therapy. Indian Dermatol Online J. 2014;5(3):374-77.

Lorkowski G. Gastrointestinal absorption and biological activities of serine and cysteine proteases of animal and plant origin: review on absorption of serine and cysteine proteases. Int J Physiol Pathophysiol Pharmacol. 2012;4(1):10-27.

Walad M, Honzikova M, Lysikova M. Systemic enzyme support: an overview. Nutrition News. 2008;4:2-5.

Targoni O, Lehmann P. Modulation of the activation threshold for autoreactive T cells via systemic enzyme therapy with phlogenzym®. J Neuroimmunol. 1995;56:66.

Lehmann P. Immunomodulation by proteolytic enzymes. Nephrology Dialysis Transplantation. 1996;11(6):953-5.

Akhtar N, Naseer R, Farooqi A, Aziz W, Nazir M. Oral enzyme combination versus diclofenac in the treatment of osteoarthritis of the knee – a double-blind prospective randomized study. Clin Rheumatol. 2004;23:410-15.

Julovi S, Xue M, Dervish S, Sambrook P, March L, Jackson C. Protease activated receptor-2 mediates activated protein C–induced cutaneous wound healing via inhibition of p38. The Am J Pathol. 2011;179(5):2233-42.

White M, Glenn M, Gomer R. Trypsin potentiates human fibrocyte differentiation. PLoS One. 2013;8(8):e70795.

White M, Gomer R. Trypsin, tryptase, and thrombin polarize macrophages towards a pro-fibrotic M2a phenotype. PLoS One. 2015;10(9):e0138748.

Mynott T, Ladhams A, Scarmato P, Engwerda C. Bromelain, from pineapple stems, proteolytically blocks activation of extracellular regulated kinase-2 in T cells. J Immunol 1999;163(5):2568-75.

Fitzhugh D, Shan S, Dewhirst M, Hale L. Bromelain treatment decreases neutrophil migration to sites of inflammation. Clinical Immunology. 2008;128(1):66-74.

Lotz-Winter H. On the pharmacology of bromelain: an update with special regard to animal studies on dose-dependent effects. Planta Med. 1990;56(03):249-53.

Gaspani L, Limiroli E, Ferrario P, Bianchi M. In vivo and in vitro effects of bromelain on PGE2 and SP concentrations in the inflammatory exudate in rats. Pharmacology. 2002;65(2):83-6.

Sahbaz A, Aynioglu O, Isik H, Ozmen U, Cengil O, Gun B et al. Bromelain: a natural proteolytic for intra-abdominal adhesion prevention. International journal of surgery. 2015;14:7-11.

Metzig C, Grabowska E, Eckert K, Rehse K, Maurer H. Bromelain proteases reduce human platelet aggregation in vitro, adhesion to bovine endothelial cells and thrombus formation in rat vessels in vivo. In Vivo. 1999;13(1):7-12

Kauss T, Moynet D, Rambert J, Al-Kharrat A, Brajot S, Thiolat D et al. Rutoside decreases human macrophage-derived inflammatory mediators and improves clinical signs in adjuvant-induced arthritis. Arthritis Res Ther. 2008;10(1):R19.

Wadworth A, Faulds D. Hydroxyethylrutosides. A review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders. Drugs. 1992;44(6):1013-32.

Sujitha B, Kripa K. Anti-arthritic and anti-Inflammatory polyphenols from Caryota urens L: A Molecular docking Analysis. Research Journal of Pharmacy and Technology. 2020;13(9):4269-73.

Sheu J, Hsiao G, Chou P, Shen M, Chou D. Mechanisms involved in the antiplatelet activity of rutin, a glycoside of the flavonol quercetin, in human platelets. J Agric Food Chem. 2004;52(14):4414-8.

Afanas' ev I, Dcrozhko A, Brodskii A, Kostyuk V, Potapovitch A. Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation. Biochem Pharmacol. 1989;38(11):1763-9.

Gerdin B, Svensjö E. Inhibitory effect of the flavonoid O-(beta-hydroxyethyl)-rutoside on increased microvascular permeability induced by various agents in rat skin. International Journal of Microcirculation, Clinical and Experimental. 1983;2(1):39-46.

Baumueller M, Rau S. Efficacy and tolerance of systemic enzyme therapy in the treatment of acute thrombophlebitis–a randomised double-blind controlled trial. Journal Phlebology and Lymphology. 2018;11(1).

Koshkin V, Kirienko A. Systemic enzyme therapy in the treatment of acute thrombosis of superficial veins in the lower extremities and postthrombophlebitic disease. International journal of immunotherapy. 2001;17(2-3-4):121-4.

Collins J. Systemic Enzyme Therapy. Your Hormones, Inc. 2008;2017. Accessed on 20th May, 2021.

Albrigo R, Andreoni C, Anello G, Barboni M, Barzaghi E, Bianchi D. Nédemax® Mese (Leucoselect®, Lymphaselect®, Bromelain) in the treatment of chronic venous disease: a multicenter, observational study. Acta Phlebologica. 2019;20(1):8-14.

Petruzzellis V, Troccoli T, Candiani C, Guarisco R, Lospalluti M, Belcaro G, et al. Oxerutins (Venoruton®): Efficacy in Chronic Venous Insufficiency: A Double-Blind, Randomized, Controlled Study. Angiology. 2002;53(3):257-63.

MacLennan W, Wilson J, Rattenhuber V, Dikland W, Vanderdonckt J, Moriau M. Hydroxyethylrutosides in elderly patients with chronic venous insufficiency: its efficacy and tolerability. Gerontology. 1994;40(1):45-52.

Cesarone M, Belcaro G, Pellegrini L, Ledda A, Di Renzo A, Vinciguerra G, et al. HR, 0-(beta-hydroxyethyl)-rutosides, in comparison with diosmin+ hesperidin in chronic venous insufficiency and venous microangiopathy: an independent, prospective, comparative registry study. Angiology. 2005;56(1):1-8.

Cesarone M, Belcaro G, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, et al. Venoruton® vs Daflon®: evaluation of effects on quality of life in chronic venous insufficiency. Angiology. 2006;57(2):131-8.

Nocker W, Diebschlag W, Lehmacher W. A 3-month, randomized double-blind dose-response study with 0-(beta-hydroxyethyl)-rutoside oral solutions. VASA. Zeitschrift fur Gefasskrankheiten. 1989;18(3):235-8.

Ippolito E, Belcaro G, Dugall M, Cesarone M, Feragalli B, Errichi B, et al. Venoruton®: post thrombotic syndrome. Clinical improvement in venous insufficiency (signs and symptoms) with Venoruton®. A five-year, open-registry, efficacy study. Panminerva medica. 2011;53(1):13-9.

Belcaro G, Cesarone M, Ledda A, Cacchio M, Ruffini I, Ricci A, et al. 5-Year control and treatment of edema and increased capillary filtration in venous hypertension and diabetic microangiopathy using O-(β-hydroxyethyl)-rutosides: A prospective comparative clinical registry. Angiology. 2008;59(1):14S-20S.

Bergstein N. Clinical study on the efficacy of O-(β-hydroxyethyl) rutoside (HR) in varicosis of pregnancy. Journal of International Medical Research. 1975;3(3):189-93.

Sohn C, Jähnichen C, Bastert G. Effectiveness of beta-hydroxyethylrutoside in patients with varicose veins in pregnancy. Zentralblatt fur Gynakologie. 1995;117(4):190-7.

Aziz Z, Tang W, Chong N, Tho L. A systematic review of the efficacy and tolerability of hydroxyethylrutosides for improvement of the signs and symptoms of chronic venous insufficiency. Journal of clinical pharmacy and therapeutics. 2015;40(2):177-85.

Poynard T, Valterio C. Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. VASA. Zeitschrift fur Gefasskrankheiten. 1994;23(3):244-50.